Quantinno Capital Management’s Lexeo Therapeutics LXEO Stock Holding History

Quantinno Capital Management’s Portfolio LXEO Stock Details LXEO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$113K	Buy	+24,293	New	+$131K	﹤0.01%	3383

Other funds holding LXEO

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Jupiter Topco New York $245B AUM

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Quantinno Capital Management's LXEO Position: Q2 2026 in Review

Quantinno Capital Management opened a new position in Lexeo Therapeutics (LXEO) in Q2 2026: 24,293 shares worth $113K. The stake represents ﹤0.01% of the portfolio and ranks #3383 among its holdings.

142 funds tracked by Wall St. Rank hold LXEO as of Q2 2026.

Quantinno Capital Management held 24,293 shares of Lexeo Therapeutics worth $113K as of Q2 2026.
Lexeo Therapeutics was a new Quantinno Capital Management position in Q2 2026.
Lexeo Therapeutics made up ﹤0.01% of Quantinno Capital Management's portfolio in Q2 2026, its #3383 holding.
142 funds tracked by Wall St. Rank held Lexeo Therapeutics as of Q2 2026.

Based on Quantinno Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.